SageView Advisory Group’s Vertex Pharmaceuticals VRTX Stock Holding History

SageView Advisory Group’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$736K	Buy	1,481 +464	+46%	+$206K	0.02%	292
2026 Q1	$454K	Sell	1,017 -285	-22%	-$133K	0.02%	372
2025 Q4	$590K	Sell	1,302 -1,995	-61%	-$860K	0.02%	335
2025 Q3	$1.29M	Sell	3,297 -548	-14%	-$229K	0.04%	234
2025 Q2	$1.77M	Sell	3,845 -133	-3%	-$61.3K	0.07%	151
2025 Q1	$1.93M	Sell	3,978 -113	-3%	-$52.7K	0.08%	132
2024 Q4	$1.65M	Sell	4,091 -2,008	-33%	-$931K	0.07%	146
2024 Q3	$2.84M	Sell	6,099 -914	-13%	-$439K	0.14%	89
2024 Q2	$3.29M	Buy	+7,013	New	+$3.04M	0.15%	78
2024 Q1	–	Sell	-6,362	Closed	-$2.84M	–	822
2023 Q4	$2.84M	Buy	6,362 +4,060	+176%	+$1.5M	0.12%	105
2023 Q3	$800K	Buy	2,302 +510	+28%	+$178K	0.05%	243
2023 Q2	$631K	Buy	1,792 +507	+39%	+$171K	0.04%	310
2023 Q1	$405K	Buy	+1,285	New	+$385K	0.03%	340

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

SageView Advisory Group's VRTX Position: Q2 2026 in Review

SageView Advisory Group increased its Vertex Pharmaceuticals (VRTX) stake by 46% in Q2 2026, buying an estimated $206K and bringing the position to 1,481 shares worth $736K. The position accounts for 0.02% of the portfolio, ranked #292.

SageView Advisory Group first reported a position in VRTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.29M in Q2 2024. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

SageView Advisory Group held 1,481 shares of Vertex Pharmaceuticals worth $736K as of Q2 2026.
SageView Advisory Group bought 464 Vertex Pharmaceuticals shares in Q2 2026, an estimated $206K.
Vertex Pharmaceuticals made up 0.02% of SageView Advisory Group's portfolio in Q2 2026, its #292 holding.
SageView Advisory Group first reported a position in Vertex Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
SageView Advisory Group's Vertex Pharmaceuticals position peaked at $3.29M in Q2 2024.
1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on SageView Advisory Group's 13F filing for Q2 2026, filed 10 Aug 2026.